PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ:STEM) today announced that it has entered into a research collaboration with the Oregon Health & Science University (OHSU) Casey Eye Institute to evaluate the Company’s proprietary HuCNS-SC® product candidate (purified human neural stem cells) as a potential treatment for retinal degeneration, a leading cause of blindness.
